Safety of switching between rituximab biosimilars in onco-hematology

Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between different biosimilars. In this prospective observati...

Descripción completa

Detalles Bibliográficos
Autores principales: Urru, Silvana A. M., Spila Alegiani, Stefania, Guella, Anna, Traversa, Giuseppe, Campomori, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966361/
https://www.ncbi.nlm.nih.gov/pubmed/33727667
http://dx.doi.org/10.1038/s41598-021-85563-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966361/
https://www.ncbi.nlm.nih.gov/pubmed/33727667
http://dx.doi.org/10.1038/s41598-021-85563-1

Ejemplares similares